Astronauts Pretend to Take Photos in the Nevada Fake Moon Bay.
NASA video as you hear & see it, is located for download at NASA site:
http://history.nasa.gov/alsj/a17/video17.html
Apollo 17 Video Library
Journal Text: 144:40:02
Journal Text: 144:47:00
Journal Text: 145:00:57
Journal Text: 145:51:22
ALL NASA FOOTAGE USED IN THIS FILM IS PUBLIC DOMAIN. THE USE OF ANY COPYRIGHTED MATERIAL IS USED UNDER THE GUIDELINES OF "FAIR USE" IN TITLE 17 § 107 OF THE UNITED STATES CODE. SUCH MATERIAL REMAINS THE COPYRIGHT OF THE ORIGINAL HOLDER AND IS USED HERE FOR THE PURPOSES OF EDUCATION, COMPARISON, AND CRITICISM ONLY. NO INFRINGEMENT OF COPYRIGHT IS INTENDED.
Moon Hoax -Astronauts & Houston Talk About High Roof Bay Fake Moon Set.
NASA video as you hear it, is located for download at NASA site:
http://history.nasa.gov/alsj/a16/video16.html
Apollo 16 Video Library
House Rock
Journal Text: 167:47:53
Moon Hoax -Astronaut Does a Ballet Dance at Ballet Crater in Fake Moon Bay.
NASA video as you hear & see it, is located for download at NASA site:
http://history.nasa.gov/alsj/a17/video17.html
Apollo 17 Video Library
Geology Station 3 at Ballet Crater
Journal Text: 144:50:23 RealVideo Clip: (3 minutes 50 seconds)
Journal Text: 144:54:04 RealVideo Clip: (4 minutes 21 seconds)
Researchers at global public health organization NSF International, Harvard Medical School, the United States Department of Defense and the National Institute for Public Health and the Environment in the Netherlands (RIVM) recently identified four unapproved, DMAA-like stimulants in six over-the-counter weight-loss and pre-workout products currently available online. The research was published in the peer-reviewed journal Clinical Toxicology.
The potentially harmful compounds – including banned stimulants 1,3-DMAA and 1,3-DMBA as well as octodrine and a newly identified DMAA analog – were not listed as ingredients in the products and may have been disguised as “2-aminoisoheptane” or extract of Aconitum kusnezoffii. These stimulants may cause adverse cardiac events, hemorrhagic strokes or sudden death, especially if taken prior to strenuous exercise or combined with caffeine. Extreme heat and dehydration may also increase the health risks.
To view the multimedia release go to:
https://www.multivu.com/players/English/8216951-nsf-international-banned-stimulants-2-aminoisoheptane/
Playing the harmonica, dancing, bowling: For Brookdale Senior Living resident Dorothy Plummer, these longtime passions bring purpose as well as pleasure to daily life. What may be surprising is that Plummer is not only 103 – she is living with dementia. Plummer embodies Brookdale’s mission of person-centered care, which focuses on sustaining individual interests and daily routines to give meaning to each person’s life. As part of National Alzheimer’s Disease Awareness Month, Brookdale is offering a free downloadable journal to help others with dementia look for ways to live life to the fullest.
“When people hear someone has Alzheimer’s, the label of the disease can unfortunately replace who the person is,” said Juliet Holt Klinger, senior director of dementia care for Brookdale. “Their life becomes shaped by the diagnosis. The things they love to do may be taken away when they don’t need to be. This can cause disengagement, potentially leading to depression, isolation, loss of appetite, weight loss, and even falls.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7722151-brookdale-senior-living-alzheimers-awareness/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Ever since Donna and John met at work three decades ago, they've had the kind of smooth, comfortable relationship that comes when attraction is accompanied by compatible interests as well as strengths and weaknesses that balance each other. They pictured their senior years as an extension of what Donna Dean calls “this nice, easy life. We didn't see the calamity that was coming.”
Brookdale Senior Living, the nation's largest dementia care provider, has created new resources for care partners as part of National Alzheimer's Awareness Month in November. The candid discussion of many of the disease's most difficult challenges includes an up-close look at Donna's and John’s lives since he developed dementia.
The couple shares on video how following John's diagnosis, they adapted and sustained daily routines, emotional connection and affection. Donna speaks of her uncertainties about how to manage her reactions to behavioral expressions, the adjustment to John's move to a dementia care community and how keeping a journal helped her logistically and emotionally.
To view the multimedia release go to:
http://www.multivu.com/players/English/7722131-brookdale-alzheimers-awareness/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
